Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

LASIK Centers’ Promotional Claims Draw FTC Complaints, Consent Order

This article was originally published in The Gray Sheet

Executive Summary

LCA-Vision, Inc. and The Laser Vision Institute will be charged $11,000 per violation per day if the centers continue to make false, unsubstantiated claims about laser eye surgery, a Federal Trade Commission order states

You may also be interested in...



Cancer, AIDS Cure Claims By Swiss Super-Zapper Maker Draw FTC Complaint

Internet ads claiming that the Super-Zapper Deluxe and Synchrometer devices are able to cure cancer, AIDS and other life-threatening diseases triggered a recent complaint from the Federal Trade Commission

FDA Seeking Civil Penalties From Clinical Investigator Disqualified By CDRH

LaHaye Center for Advanced Eye Care of Lafayette, Louisiana will have until Dec. 20 to respond to an FDA administrative complaint filed Oct. 11

MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In

The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT018124

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel